Andreas Clemens | Academic Influence

Andreas Clemens's AcademicInfluence.com Rankings

Andreas Clemens

Computer Science

#11702

World Rank

#12430

Historical Rank

Machine Learning

#5383

World Rank

#5453

Historical Rank

Artificial Intelligence

#5801

World Rank

#5889

Historical Rank

Database

#8778

World Rank

#9216

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Andreas Clemens's Degrees

Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Andreas Clemens Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Andreas Clemens is a German physician. He is an internist, endocrinologist and diabetologist. His main interest is the investigation and development of drugs in the field of cardiology, endocrinology, ophthalmology and very rare diseases.

(See a Problem?)

Andreas Clemens's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity (2010) (1426)
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients (2011) (368)
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor (2009) (342)
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. (2009) (303)
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. (2012) (241)
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice (2012) (237)
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. (2010) (218)
Effective elimination of dabigatran by haemodialysis (2013) (212)
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. (2010) (154)
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. (2013) (140)
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment (2016) (133)
Stroke prevention in atrial fibrillation--an Asian stroke perspective. (2013) (131)
Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution (1999) (128)
Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate (2010) (127)
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. (2014) (112)
Patient outcomes using the European label for dabigatran (2013) (105)
Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation (2012) (102)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). (2016) (97)
Interpretation of point-of-care INR results in patients treated with dabigatran. (2012) (96)
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. (2012) (75)
Adsorption of Dabigatran Etexilate in Water or Dabigatran in Pooled Human Plasma by Activated Charcoal in Vitro. (2009) (73)
Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide. (1991) (69)
Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes (2014) (67)
PACAP is a stimulator of neurogenic contraction in guinea pig ileum. (1993) (67)
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada (2012) (65)
The Discovery of Dabigatran Etexilate (2012) (59)
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial (2017) (58)
Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database (2012) (56)
The biological relevance of gastric neuroendocrine tumors. (1996) (56)
Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). (2015) (55)
The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation (2011) (55)
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation (2012) (55)
Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions? (2014) (54)
Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation (2014) (50)
Pharmacometric Characterization of Dabigatran Hemodialysis (2013) (49)
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective (2016) (48)
Pituitary adenylate cyclase activating polypeptide (PACAP) is a potent relaxant of the rat ileum (1993) (47)
Pituitary adenylate cyclase-activating peptide is a potent modulator of human colonic motility. (1993) (47)
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration (2020) (44)
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement (2009) (40)
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification (2012) (37)
Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort (2019) (36)
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment (2013) (36)
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria (2014) (35)
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate (2011) (34)
The asthma–COPD overlap syndrome: do we really need another syndrome in the already complex matrix of airway disease? (2016) (33)
Relaxant effect of xenin on rat ileum is mediated by apamin-sensitive neurotensin-type receptors. (1997) (32)
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: No increased risk of bleeding (2012) (29)
Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines. (2004) (29)
Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. (1999) (28)
Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials (2015) (25)
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile (2012) (25)
Vasoactive intestinal polypeptide induces neurogenic contraction of guinea-pig ileum. Involvement of acetylcholine and substance P (1992) (23)
Pharmacokinetics and Pharmacodynamics of Dabigatran 75 mg b.i.d. in Patients With Severe Chronic Kidney Disease. (2016) (23)
Thromboprophylaxis with dabigatran etexilate in patients over seventy-five years of age with moderate renal impairment undergoing or knee replacement (2012) (23)
Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study (2019) (22)
COMPARISON OF DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE: THE RE-LY® TRIAL (2014) (22)
Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study (2019) (21)
Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials (2012) (21)
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study (2018) (20)
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. (2012) (20)
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. (2015) (20)
Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. (2014) (19)
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations (2021) (19)
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. (2016) (18)
The J558 VH CDR3 region contributes little to antibody avidity; however, it is the recognition element for cognate T cell control of the alpha(1-->3) dextran-specific antibody response. (1998) (18)
Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records (2016) (18)
Differences in COPD Exacerbation Risk Between Women and Men: Analysis From the UK Clinical Practice Research Datalink Data. (2019) (18)
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING) (2016) (17)
Prediction and prevention of exacerbations and mortality in patients with COPD (2016) (17)
Quality of INR Control and Outcomes Following Venous Thromboembolism (2012) (16)
Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US (2014) (16)
The use of dabigatran according to body mass index : the RE-LY experience (2014) (16)
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study (2020) (15)
Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement: A Systematic Review (2012) (15)
Human galanin modulates human colonic motility in vitro. Characterization of structural requirements. (1996) (12)
Efficacy and Safety Profile of Dabigatran Etexilate Compared with Enoxaparin in Primary Venous Thromboembolism Prevention after Total Knee or Hip Replacement Surgery in Patients Over 75 Years (2008) (12)
Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study (2020) (12)
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. (2012) (11)
Insulin-dependent diabetes mellitus: Islet changes in relation to etiology and pathogenesis (1997) (11)
Expression and distribution of the prolactin receptor in normal rat liver and in experimental liver cirrhosis. (2001) (11)
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis (2015) (10)
Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management (2012) (10)
Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect (2018) (10)
Erratum to: Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery (2012) (10)
[Insulin-dependent diabetes mellitus. Current aspects of morphology, etiology and pathogenesis]. (1996) (10)
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting (2016) (10)
Acceleration of Dabigatran Elimination by Activated Charcoal Perfusion and Hemodialysis in a Pig Model. (2012) (9)
Abstract 13303: Effective Elimination of Dabigatran with Haemodialysis: A Phase I Single Centre Study in Patients with End-Stage Renal Disease (2011) (9)
Insulin-independent diabetes mellitus. Current aspects of its morphology, etiology, and pathogenesis (1996) (9)
Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery. (2008) (8)
Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis (2022) (8)
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. (2012) (8)
Abstract 15537: Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial (2012) (7)
Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. (2021) (7)
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study (2017) (7)
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. (2012) (7)
Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects (2013) (7)
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data (2020) (7)
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database (2020) (7)
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study (2018) (6)
Critical Appraisal Of Network Meta-Analyses Evaluating The Efficacy And Safety Of New Oral Anticoagulants In Atrial Fibrillation Stroke Prevention Trials. (2014) (6)
Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). (2016) (6)
Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies (2022) (6)
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. (2017) (6)
Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study (2021) (6)
Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis—A simulation analysis (2016) (6)
DABIGATRAN DOES NOT PROLONG THE QTC INTERVAL WITH SUPRATHERAPEUTIC EXPOSURE: A THOROUGH QTC STUDY (2011) (5)
The novel brain-gut peptide PACAP induces in vitro relaxation of the rat ileum (1992) (4)
Abstract 14413: Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopedic Surgery (2011) (4)
Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. (2016) (4)
Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age (2012) (4)
Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery (2015) (4)
Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study (2021) (4)
Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal (2010) (3)
Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study (2017) (3)
O215 Results of the 1st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants (2014) (3)
[Etiology and pathogenesis of insulin-dependent diabetes mellitus]. (1996) (3)
[Optic neuritis in non-Hodgkin's lymphoma]. (1992) (3)
Abstract 11087: Benefits of Dabigatran versus Warfarin in Hypertensive Patients With Atrial Fibrillation: Results From The Re-ly Trial (2013) (2)
150 MG DABIGATRAN ETEXILATE ONCE DAILY HAS A GOOD SAFETY PROFILE AND COMPARABLE EFFICACY TO ENOXAPARIN FOR PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY IN PATIENTS OVER 75 YEARS OF AGE (2010) (2)
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study (2015) (2)
Osteoporosis onset in patients prescribed ICS for COPD: matched cohort study (2018) (2)
Assessment of Cross-Reactivity in Three Different Fecal Occult Blood Test Systems with Dabigatran and Dabigatran Etexilate: Identification of Useful Test Methods (2012) (2)
RE-LY and RELY-ABLE : Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years (2013) (2)
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events (2023) (2)
A model to quantify the influence of treatment patterns and optimize outcomes in nAMD (2022) (2)
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab (2023) (2)
S35 Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate copd: the crystal study (2016) (2)
Incidence of Vascular Outcomes in Patients with Atrial Fibrillation (2011) (1)
150 MG DABIGATRAN ETEXILATE SHOWED SIMILAR EFFICACY AND APPARENTLY LOWER BLEEDING COMPARED WITH ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN MODERATELY RENALLY IMPAIRED PATIENTS AFTER TOTAL KNEE OR HIP REPLACEMENT SURGERY (2010) (1)
Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial (2018) (1)
NO DIFFERENCE DETECTED IN EFFICACY OF DABIGATRAN ETEXILATE WHEN INITIAL DOSING WAS DELAYED: A POST HOC ANALYSIS OF POOLED DATA FROM THE EUROPEAN PIVOTAL PHASE III TRIALS (2010) (1)
Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials (2011) (1)
Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials (2011) (1)
Dabigatran Etexilate : Pharmacology of the New, Oral Direct Thrombin Inhibitor (2011) (1)
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach. (2019) (1)
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile (2012) (1)
Reversal of dabigatran clotting activity in the rat ex vivo by a specific and selective antibody fragment antidote: are there non-specific effects on warfarin, rivaroxaban and apixaban? (2013) (1)
Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care (2019) (1)
Association between ICS therapy for COPD and diabetes onset and progression (2018) (1)
Design and rationale of GLORIA-AF: A Global Registry Program on Long- Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (2013) (1)
Comparative Efficacy and Safety Of Dabigatran Etexilate and Rivaroxaban For The Treatment Of Deep Vein Thrombosis and Pulmonary Embolism (2013) (1)
[Optimized diabetes therapy in type 2 diabetics]. (2003) (1)
Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial (2013) (1)
PCV56 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY THAT HAVE MODERATE IMPAIRMENT OF RENAL FUNCTION (2009) (1)
PSS8 - IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON-INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS): THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) (2018) (1)
GLP-I(7-36amide) increases insulin secretion from pancreatic islets in cirrhotic rats (1998) (0)
Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study (2016) (0)
Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study (2013) (0)
IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2023) (0)
Abstract 11473: Dabigatran Treatment Simulation in Patients Undergoing Maintenance Hemodialysis (2015) (0)
Abstract WP269: Increased Sensitivity to recombinant Tissue Plasminogen Activator (rtPA)-induced Lysis in vitro of Thrombi Produced in Human Platelet Rich Plasma containing Dabigatran (2013) (0)
THE GLOBAL REGISTRY PROGRAM ON LONG-TERM ORAL ANTI-THROMBOTIC TREATMENT IN PATIENTS WITH ATRIAL FIBRILLATION (GLORIA-AF): FIRST ASSESSMENT OF BASELINE CHARACTERISTICS OF DABIGATRAN AND VKA COHORTS IN NORTH AMERICA (2014) (0)
PCV54 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE 150 MG FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS AGED OVER 75 YEARS UNDERGOING TOTAL HIP OR KNEE ARTHROPLASTY (2009) (0)
A model to quantify the influence of treatment patterns and optimize outcomes in nAMD (2022) (0)
Abstract 14178: Incidence of Bleeding Events in Patients with Atrial Fibrillation (2012) (0)
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database [Corrigendum] (2020) (0)
Typ-1-Diabetes (1999) (0)
[Normalization of blood pressure and lipids in patients with diabetes]. (2003) (0)
Country-wise recruitment of treatment-naïve patients with BRVO. (2020) (0)
Health care resource utilization (HCRU) in early and late diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients in UK primary care (2019) (0)
Dabigatran Users With Non-Valvular Atrial Fibrillation in the Us: A Characterization of Dabigatran Initiators and Switchers. (2014) (0)
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study (2016) (0)
Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial (2017) (0)
P01. [109] Respiratory Symptoms And Ventilatory Functions In Women Exposed To Domestic Cooking Fuel In A Rural Community In Lagos State, South West, Nigeria (2017) (0)
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials (2022) (0)
T cell epitopes within the CDR3 region of α(1→3) dextran (Dex)-specific IgG antibodies restrict the variability of the immune responses to this “thymus-independent” antigen through an idiotype-specific cognate interaction between T and B cells (1997) (0)
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) in patients with moderate COPD: Results from the CRYSTAL study (2017) (0)
SAFETY PROFILE OF DABIGATRAN ETEXILATE IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY CONCOMITANTLY TAKING ASPIRIN OR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: FINDINGS IN 3 PHASE III TRIALS (2010) (0)
10. The Discovery of Dabigatran Etexilate (2012) (0)
Impact of retinal fluid-free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and HARRIER studies. (2022) (0)
Epidemiological Data On the Incidence of Co-Morbidities and Co-Medications in Patients Undergoing Total Hip or Knee Replacement Surgery: Real-World Study and Phase III Clinical Trials. (2012) (0)
Correction: Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria (2014) (0)
Abstract 13877: Inflammatory Activity Correlates With Severity of Heart Failure - The Association of High Sensitive CRP With Left Ventricular Ejection Fraction, ProBNP and NYHA-Class in a Real-World Cohort (2019) (0)
C0190: Switching from Low Molecular Weight Heparin to Dabigatran in Patients Undergoing Elective Total Hip or Knee Replacement Surgery is Effective with a Good Safety Profile (2014) (0)
Guidance adherent dabigatran etexilate treatment versus warfarin in the RE-LY population: an analysis on the basis of the European label recommendations for dabigatran etexilate (2013) (0)
Xenin relaxes precontracted rat ileal smooth muscle in vitro: Structure activity relationship and binding studies (1995) (0)
Motor effects of xenin on circular human colonic strips: Mode of action and structure function analysis (1995) (0)
GLP-1 Increases Insulin Secretion from Pancreatic Islets in Cirrhotic Rats (1998) (0)

This paper list is powered by the following services:

Other Resources About Andreas Clemens

en.wikipedia.org

What Schools Are Affiliated With Andreas Clemens?

Andreas Clemens is affiliated with the following schools: